William Cooper
Internal Medicine · Thomasville, GANPI 1477512663
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 95 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$301
- Pfizer$213
- Astellas Pharma US Inc$155
- Novo Nordisk$145
- Amgen$118
- AbbVie$115
- plus $553 from 15 others
Across 63 payments — averaging $16,338 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$910K
- Genentech, Inc.$57K
- Medtronic$32K
- Boehringer Ingelheim$19K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Food & beverage$1,601100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $301 |
| Pfizer | 14 | $213 |
| Astellas Pharma US Inc | 9 | $155 |
| Novo Nordisk | 9 | $145 |
| Amgen | 7 | $118 |
| AbbVie | 6 | $115 |
| AstraZeneca | 5 | $81 |
| Novartis | 4 | $80 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Johnson & Johnson | 5 | $69 |
| Lilly USA, LLC | 4 | $68 |
| LEO Pharma Inc. | 1 | $27 |
| Incyte Corporation | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Insmed, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $7 |
How this compares
$1,601 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 217 | $188,188 |
| FarxigaDapagliflozin Propanediol | 174 | $145,539 |
| JardianceEmpagliflozin | 142 | $111,561 |
| OzempicSemaglutide | 99 | $104,479 |
| TrulicityDulaglutide | 55 | $51,700 |
| XareltoRivaroxaban | 35 | $27,832 |
| RybelsusSemaglutide | 13 | $24,211 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $24,210 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $22,882 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 70 | $21,437 |
| EntrestoSacubitril/Valsartan | 25 | $16,174 |
| MyrbetriqMirabegron | 34 | $15,515 |
| Potassium Chloride | 511 | $12,453 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 55 | $12,248 |
| Atorvastatin Calcium | 1,086 | $11,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $213 | $195,628233 claims |
| AstraZenecaFarxiga | $81 | $145,539174 claims |
| Novo NordiskOzempic, Rybelsus | $145 | $128,690112 claims |
| Boehringer IngelheimJardiance | $19 | $111,561142 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix | $301 | $80,776196 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $68 | $63,14266 claims |
| Johnson & JohnsonXarelto | $69 | $27,83235 claims |
| AbbVieLinzess, Synthroid | $115 | $17,385109 claims |
| NovartisEntresto | $80 | $16,17425 claims |
| Astellas Pharma US IncMyrbetriq | $155 | $15,51534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Thomasville
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.